Join our panel of experts from around the world for this compelling event presenting a view from the front line on the management of diabetes patients and comorbidities in the context of COVID-19.

With telehealth and remote treatment on the rise, a unique and international group of experts will analyse how rapid point-of-care testing may benefit patients with diabetes in the COVID-19 healthcare landscape and beyond.

Screening and monitoring of diabetes and cardiovascular patients is even more critical nowadays. According to the World Health Organisation, individuals may be more susceptible to severe COVID-19 and death if they have a noncommunicable disease, such as diabetes, high blood pressure, cardiac disease, kidney disease, chronic lung disease, cerebrovascular disease or cancer. ^[1] Diabetes has not yet been shown to increase the likelihood of SARS-CoV-2 infection, but progression to severe illness is more likely in people with diabetes.2 The frequency of diabetes among COVID-19 patients requiring hospitalisation or intensive care is two to three times higher than in the overall population, and mortality rates in those with diabetes are also higher. ^{[2] [3] [4] [5] [6] [7] [8]}.

Point-of-care testing for HbA1c aids in achieving improved glycaemic control with just one office visit. ^{[9] [10] [11] [12]}

In this educational event, the group of experts will share new strategies for the management of diabetes and comorbidities and how countries around the world are successfully adopting rapid HbA1c and lipid pointof-care testing for the continued remote management of diabetes and cardiovascular patients during COVID-19 and beyond.